XenoPort, Inc. (NASDAQ:XNPT)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.

Results 1 - 20 of 26 : 1 2 Next »

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 11/15/2013 4:00:18 AM : Outperform Start Price: $5.15 XNPT Score: -8.84

IHS monthly

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 5:31:32 PM : Underperform Start Price: $4.63 XNPT Score: +6.02

Short. Crappy company sells stock much more than product.

Recs

0
Member Avatar Wmjack50 (< 20) Submitted: 9/25/2012 10:48:37 AM : Outperform Start Price: $10.99 XNPT Score: -89.10

prodrugs get approval much more quickly than new drugs

Recs

0
Member Avatar RBuskey106 (41.97) Submitted: 4/4/2012 6:03:38 PM : Outperform Start Price: $4.65 XNPT Score: -29.99

Chart play

Recs

2
Member Avatar siri22 (< 20) Submitted: 10/19/2011 3:11:39 PM : Outperform Start Price: $5.37 XNPT Score: -66.76

Below pre approval price?

Recs

0
Member Avatar projectchris (39.21) Submitted: 6/1/2011 9:38:27 AM : Outperform Start Price: $7.77 XNPT Score: -81.01

just tracking

Recs

0
Member Avatar Woopde (< 20) Submitted: 4/8/2011 1:21:56 AM : Outperform Start Price: $9.77 XNPT Score: -95.61

FDA

Recs

0
Member Avatar KimLanners (< 20) Submitted: 4/7/2011 10:46:52 AM : Outperform Start Price: $10.15 XNPT Score: -98.32

biotech comeback us technicals

Recs

0
Member Avatar franktejon (< 20) Submitted: 7/7/2010 10:25:48 PM : Outperform Start Price: $6.56 XNPT Score: -106.75

strong buy

Recs

0
Member Avatar syazic (70.06) Submitted: 2/26/2010 9:37:08 AM : Outperform Start Price: $8.40 XNPT Score: -118.08

XNPT oversold by shorties.. Intrinsic value is $10-18.

Recs

0
Member Avatar LegitCompute (< 20) Submitted: 2/24/2010 4:03:29 AM : Outperform Start Price: $8.09 XNPT Score: -116.50

This stock is likely to sky rocket from its current price of $8.16 within the next few weeks possibly a couple months. The reason behind this is because they just had a better than expected earnings report, and they have the funds to fund their future research. They also just need to revise their new restless leg drug to be able to get it approved by the FDA. This is definitely a bargain stock at the moment, and soon to be a very profitable stock.

Recs

0
Member Avatar TraderAsh123 (< 20) Submitted: 2/23/2010 11:19:27 PM : Outperform Start Price: $8.22 XNPT Score: -117.72

fill the gap

Recs

2
Member Avatar PapiShasho (< 20) Submitted: 2/19/2010 1:30:30 PM : Outperform Start Price: $7.32 XNPT Score: -107.86

oversold

Recs

0
Member Avatar hansjang (< 20) Submitted: 2/19/2010 7:48:26 AM : Outperform Start Price: $6.82 XNPT Score: -103.69

It should be wait what FDA say for this REJECT.
And, we can do something for this company.
I am waiting for a while.
I believe what XNPT did well.

Recs

1
Member Avatar BuffetsMentor (21.30) Submitted: 2/18/2010 1:47:33 PM : Outperform Start Price: $6.66 XNPT Score: -101.98

bizzounce

Recs

0
Member Avatar riegonla (39.13) Submitted: 2/9/2010 9:53:06 PM : Outperform Start Price: $18.85 XNPT Score: -159.34

25US$ Feb 2011

Recs

1
Member Avatar tenmiles (99.60) Submitted: 1/28/2010 10:26:36 AM : Outperform Start Price: $18.92 XNPT Score: -155.90

Getting restless for a long - playing an anticipated FDA pop in February. Long at $18.82

Recs

0
Member Avatar Alex1963 (28.48) Submitted: 9/17/2009 1:18:45 PM : Outperform Start Price: $24.50 XNPT Score: -167.19

from article in Morn* 9/17/09
announced positive results Thursday from a Phase IIb clinical trial for XP13512 for neuropathic pain associated with post-herpetic neuralgia. The drug candidate was successful in demonstrating statistically significant results over placebo at all dosing levels, and we plan to slightly raise our fair value estimate in the wake of this news. The 14-week, double-blind trial evaluated the safety and efficacy of XP13512 and had a total enrollment of 375 subjects with PHN who experienced pain following the healing of the herpes zoster (shingles) skin rash for at least three months. XP13512 was statistically significan t on the primary endpoint of the trial, which was improvement from baseline in the 24-hour average pain intensity score. We think this is great news for XenoPort, which experienced a setback with XP13512 in April, when the drug failed a Phase II study for pain associated with diabetes. XenoPort has partnered with GlaxoSmithKline GSK on the drug, which is still on track for final approval from the Food and Drug Administration for restless leg syndrome, having met all primary goals in its Phase III trials.

Recs

0
Member Avatar TMFBiologyFool (96.16) Submitted: 11/10/2008 11:00:30 AM : Outperform Start Price: $34.50 XNPT Score: -204.91

Purely a value play. Doesn't deserve a 13% drop because Solzira's NDA has to be reformatted.

Recs

0
Member Avatar mukwonago53149 (< 20) Submitted: 1/16/2008 9:24:14 PM : Underperform Start Price: $61.40 XNPT Score: +143.12

http://www.fool.com/investing/small-cap/2008/01/16/stocks-on-bubble-watch.aspx

Results 1 - 20 of 26 : 1 2 Next »

Featured Broker Partners


Advertisement